Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt

Phase 3

Completed

• Conditions: Convalescent Plasma; Immunoglobulins; Egypt; Plasma; Covid19
• Interventions: Biological: Convalescent Plasma

• Registration Number: NCT04816942
• Lead Sponsor: Ministry of Health and Population, Egypt

Brief Summary

One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from individuals who have recovered from COVID-19 (Refs. 1-4). Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARSCoV-2 (the virus that causes COVID-19) is being studied for administration to patients with COVID-19. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic (Refs. 5-7).

Although promising, convalescent plasma has not yet been shown to be safe and effective as a treatment for COVID-19. Therefore, it is important to study the safety and efficacy of COVID19 convalescent plasma in clinical trials. This guidance provides recommendations to health care providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency. This guidance also provides recommendations to blood establishments on the collection of COVID-19 convalescent plasma..

Detailed Description

laboratory-confirmed patients using qRT-PCR will be enrolled in the study. Eligibility criteria for recipients are ; laboratory-confirmed SARS-CoV-2, Severe or immediately life-threatening. Severe disease defined as one or more of the following; shortness of breath( dyspnoea), respiratory frequency≥ 30/min, blood oxygen saturation ≤93%, a partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300, and lung infiltrates \>50% within 24-48 hours. While a life-threatening disease is defined as one or more of the following; respiratory failure, need for mechanical ventilation, septic shock and multiple organ dysfunction or failure.

Intervention: All patients included in the study provided will be administered with two plasma units (each unit is 200cc).

Primary measure is the degree of clinical improvement among the COVID-19 patients who receive CPT within seven days as compared with the patients who receive after seven days. Case Fatality will be assessed among the enrolled cases

Study Timeline

• Study Start: 2020-04-23
• Primary Completion: 2020-07-21
• Study Completion: 2020-10-12
• Study First Submitted: 2021-02-12
• Status Verified: 2021-03
• Study First Submitted QC: 2021-03-24
• Last Update Submitted: 2021-03-24
• Study First Posted: 2021-03-25
• Last Update Posted: 2021-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Laboratory confirmed COVID-19. Severe or immediately life-threatening COVID-19,

Exclusion Criteria Not fitting inclusion criteria

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Convalescent Plasma	Convalescent Plasma	Patients receiving Two units of ABO compatible COVID-19 convalescent plasma will be administered.P

Primary Outcome Measures

Name	Time	Method
COVID-19 Cure rate	30 days	Primary measure was the degree of clinical improvement among the COVID-19 patients who received CPT within seven days as compared with the patients who received after seven days

Trial Locations

Locations (1)

Ministry of Health; 🇪🇬 Cairo, Giza, Egypt